U.S.Cellular customers can today pick up the HTC One V online and the device will be in-store starting Friday. While the Android handset may be a little overshadowed by its big brothers the One X and One S, the One V, as you'll recall from our review, does pack a pretty good punch for its price, which is $129.99 after a $100 mail-in rebate . Running Android 4.0 out of the box and complemented with the latest addition of Sense UI the One V is great looking and feels wonderful in the hand. It has the familiar 'chin' that we saw on the HTC Hero and Legend and whilst its 1GHz processor may not be as powerful as the One X and One S it certainly does a good job of making things run smoothly.
You can order the HTC One V online here and we have the full press release below for your viewing pleasure.
Tufts Medical Center researchers receive $10 million NIH grant to test blood clot prevention drugPublic release date: 3-Jul-2012 [ | E-mail | Share ]
Contact: Julie Jette jjette@tuftsmedicalcenter.org 617-636-3265 Tufts Medical Center
Boston, Mass. (July 3, 2012) Tufts Medical Center researchers are developing a first-of-its-kind drug to prevent deadly blood clots in heart disease patients, without the risk of serious bleeding associated with current medications. The National Heart, Lung, and Blood Institute of the National Institutes of Health has just awarded the team led by Athan Kuliopulos, MD, PhD, a $10 million grant to start testing a drug based on this novel technology.
"If our study works, it's potentially game-changing and could become part of the standard of care for patients being treated for coronary artery blockages," said Kuliopulos, Director of the Hemostasis and Thrombosis Lab at Tufts Medical Center.
Heart disease is the leading cause of death in the United States. The new approach could benefit patients who have had heart attacks or who need cardiac catheterization procedures to prop open clogged arteries with a stent. These patients face increased risk for blood clots that can cause heart attack and death. To reduce these risks, patients are currently treated with anti-clotting drugs, which increase their risk of life-threatening bleeding problems.
In a study to be published today in the journal Circulation, Tufts Medical Center researchers have discovered a mechanism to inhibit the ability of platelets to form clots without increasing the risk of bleeding. The new approach uses pepducins, which are able to travel inside cells to block receptors and inhibit molecular pathways that stimulate clot formation. By contrast, most approved drugs block receptors on the outside of cells. If successful, this new strategy could lead to an entirely new class of drugs.
The pepducin, PZ-128, inhibits PAR1, a platelet protein that stimulates clotting. When added to human blood samples, PZ-128 appears to inhibit clotting without affecting bleeding markers. It also clears out of the blood stream within hours, which should reduce the risk of long-term bleeding problems.
"Anytime you have a new molecule that exploits a novel mechanism of action, it's very exciting and the benefit to patients is potentially tremendous,'' said Carey Kimmelstiel, MD, Director of the Cardiac Catheterization Laboratory and Interventional Cardiology at Tufts Medical Center. "A new technology that can inhibit platelet function without increasing bleeding would be enormously powerful."
The next step is to evaluate the safety and effectiveness of the pepducin in humans. The five-year, $10 million NIH grant will fund the early stages of drug development. Researchers will first conduct a Phase I clinical trial in healthy human volunteers to determine whether the drug is safe. If successful, the grant will cover a multi-center Phase II clinical trial in 800 patients.
The research is the result of a long-term collaborative effort between laboratory scientists and the clinicians in the Cardiac Catheterization Laboratory at Tufts Medical Center.
"These exciting advances would not have been possible without this strong partnership," said Kuliopulos. "It is critical for researchers to have an understanding and appreciation of the clinical issues and practical matters concerning the real-world application of the drug."
###
About Tufts Medical Center and Floating Hospital for Children
Tufts Medical Center is an exceptional, not-for-profit, 415-bed academic medical center that is home to both a full-service hospital for adults and Floating Hospital for Children. Conveniently located in downtown Boston, the Medical Center is the principal teaching hospital for Tufts University School of Medicine. Floating Hospital for Children is the full-service children's hospital of Tufts Medical Center and the principal pediatric teaching hospital of Tufts University School of Medicine. Tufts Medical Center is affiliated with seven community hospitals and with New England Quality Care Alliance, its community physicians' network. For more information, please visit www.tuftsmedicalcenter.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Tufts Medical Center researchers receive $10 million NIH grant to test blood clot prevention drugPublic release date: 3-Jul-2012 [ | E-mail | Share ]
Contact: Julie Jette jjette@tuftsmedicalcenter.org 617-636-3265 Tufts Medical Center
Boston, Mass. (July 3, 2012) Tufts Medical Center researchers are developing a first-of-its-kind drug to prevent deadly blood clots in heart disease patients, without the risk of serious bleeding associated with current medications. The National Heart, Lung, and Blood Institute of the National Institutes of Health has just awarded the team led by Athan Kuliopulos, MD, PhD, a $10 million grant to start testing a drug based on this novel technology.
"If our study works, it's potentially game-changing and could become part of the standard of care for patients being treated for coronary artery blockages," said Kuliopulos, Director of the Hemostasis and Thrombosis Lab at Tufts Medical Center.
Heart disease is the leading cause of death in the United States. The new approach could benefit patients who have had heart attacks or who need cardiac catheterization procedures to prop open clogged arteries with a stent. These patients face increased risk for blood clots that can cause heart attack and death. To reduce these risks, patients are currently treated with anti-clotting drugs, which increase their risk of life-threatening bleeding problems.
In a study to be published today in the journal Circulation, Tufts Medical Center researchers have discovered a mechanism to inhibit the ability of platelets to form clots without increasing the risk of bleeding. The new approach uses pepducins, which are able to travel inside cells to block receptors and inhibit molecular pathways that stimulate clot formation. By contrast, most approved drugs block receptors on the outside of cells. If successful, this new strategy could lead to an entirely new class of drugs.
The pepducin, PZ-128, inhibits PAR1, a platelet protein that stimulates clotting. When added to human blood samples, PZ-128 appears to inhibit clotting without affecting bleeding markers. It also clears out of the blood stream within hours, which should reduce the risk of long-term bleeding problems.
"Anytime you have a new molecule that exploits a novel mechanism of action, it's very exciting and the benefit to patients is potentially tremendous,'' said Carey Kimmelstiel, MD, Director of the Cardiac Catheterization Laboratory and Interventional Cardiology at Tufts Medical Center. "A new technology that can inhibit platelet function without increasing bleeding would be enormously powerful."
The next step is to evaluate the safety and effectiveness of the pepducin in humans. The five-year, $10 million NIH grant will fund the early stages of drug development. Researchers will first conduct a Phase I clinical trial in healthy human volunteers to determine whether the drug is safe. If successful, the grant will cover a multi-center Phase II clinical trial in 800 patients.
The research is the result of a long-term collaborative effort between laboratory scientists and the clinicians in the Cardiac Catheterization Laboratory at Tufts Medical Center.
"These exciting advances would not have been possible without this strong partnership," said Kuliopulos. "It is critical for researchers to have an understanding and appreciation of the clinical issues and practical matters concerning the real-world application of the drug."
###
About Tufts Medical Center and Floating Hospital for Children
Tufts Medical Center is an exceptional, not-for-profit, 415-bed academic medical center that is home to both a full-service hospital for adults and Floating Hospital for Children. Conveniently located in downtown Boston, the Medical Center is the principal teaching hospital for Tufts University School of Medicine. Floating Hospital for Children is the full-service children's hospital of Tufts Medical Center and the principal pediatric teaching hospital of Tufts University School of Medicine. Tufts Medical Center is affiliated with seven community hospitals and with New England Quality Care Alliance, its community physicians' network. For more information, please visit www.tuftsmedicalcenter.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Nintendo hasn't incorporated any features in the Wii U to discourage used-game sales. Nintendo's Executive VP of Sales and Marketing, Scott Moffitt, told Gamespot at E3 that Nintendo isn't overtly concerned with combating used-game sales: "I don't know if we have a formal position on used-game sales. It is a reality in the marketplace," Moffitt said. "We're not trying to circumvent that." He didn't mention any specifics about online passes or DLC in Nintendo titles.
The Wii U's online strategy begins with the Miiverse, as Moffitt describes it, and Nintendo is focused on using its online capabilities to enhance social features, gameplay and "the connectedness gamers feel with one another."
Online multiplayer is a part of Nintendo's online strategy for Wii U, but not its entire focus. "Online multiplayer is one part of it, and certainly Wii U will enable the same online multiplayer features that have become popular in some of the competing consoles, but that's really one piece of the online gaming network," Moffitt said. "Our vision is broader."
Apparently Nintendo's vision isn't broad enough to include online multiplayer for Pikmin 3 ? though perhaps that's a case of not seeing the forest for the Pikmin.
The Wii U's output ranges from 480i to 1080p, and Moffitt said he thinks Nintendo's first-party titles will run at 1080p.
11:00 AM: Grambling State University has approved a three-year contract for football coach Doug Williams. Williams had sued the school after he was promised a contract when he took the job in March 2011, but was told he would have to negotiate a new one.
9:00 PM: U.S. Marine Corporal Christopher Farias threw out the first pitch for Sunday's game at Dodger Stadium - and was surprised to find out that the catcher was his father, Lawrence.
8:45 PM: Video of the South Atlantic League holding its All-Star Game Home Run Derby on the deck of the U.S.S. Yorktown aircraft carrier in Charleston, South Carolina.
8:30 PM: A Czech basketball magazine asked Washington Wizards player Jan Vesely: "You're the only white playing for the Wizards. Is it odd for you?" Vesley's response: "No, it's not, we are all pros, nobody looks on the color of skin. The important thing is, we have to pull the same rope."
8:15 PM: An L.A. Kings fan (or perhaps two) took out classified ads in the Newark Star Ledger & Vancouver Province telling Devils & Canucks fans "Better luck next year".
8:00 PM: During a speech at a church event at San Diego's Qualcomm Stadium Sunday, New York Jets QB Tim Tebow said that Mel Gibson's movie "Braveheart" "had the biggest impact on my life."
7:45 PM: Former high school football star Brian Banks, who spent five years in prison on rape charges but was cleared when his alleged victim admitted she lied, has created a Kickstarter account to raise money to make a documentary about his experience.
7:30 PM: New England Patriots owner Robert Kraft was announced as one of this year's 18 new inductees into the Columbia University Athletics Hall of Fame.
7:15 PM: L.A. Kings Insider notes that the puck on the ice at the end of the Stanley Cup-clinching Game 6 was last seen in the glove of the New Jersey Devils' Patrik Elias.
7:00 PM: Arkansas Razorbacks offensive lineman Jason Peacock was sentenced to 10 days in jail & one year probation after pleading guilty to stealing another student's credit card.
6:45 PM: A man in Hopatcong, New Jersey called local police claiming he was the President & he wanted to talk to Jets QB Tim Tebow. When police went to look for the man, they found him his mother's bedroom closet under some pillows.
6:30 PM: Indianapolis Colts QB Andrew Luck & pro golfer Michelle Wie were among the 5,088 Stanford students who received their degrees in graduation ceremonies Sunday.
6:15 PM: Three soccer players for the Toronto FC MLS club were arrested on public intoxication charges after fighting outside a Houston nightclub early Monday morning.
6:00 PM: Ohio State released full details of Urban Meyer's contract, including an out clause that allows him to leave the job & still collect $1.5 million a year if more NCAA violations from the past pop up.
5:45 PM: The attorney for Tampa Bay Buccaneers cornerback Aqib Talib says the case against his client on assault with a deadly weapons charges has been dismissed.
As a follow on to my blogpost on High Value Data Information Governance, I thought I would share some additional benefits that company's often realize when they have been able to effectively identify and assess risk for their most valuable information.
While this can be a daunting task for a company, the business benefits of doing so are numerous and span beyond simply "IT Security" into Enterprise Risk Management, Infrastructure Management,?Legal and other business areas.? Here are a just a few example of the reoccurring benefits that I see with my Fortune 500 clients:
Business Benefits:
? ?Improved collaboration and cross-functional decision making across business units.
?? Improved business engagement and buy-in to the company?s Information Security Program
?? Improved ties of security investments to any current or emerging Enterprise Risk Management efforts.
?? Data Protection investments are more effectively prioritized and deployed to protect the company?s most valuable information:
BCP/DR ? prioritization of Business Continuity Plans/Disaster Recovery resources and efforts.
Infrastructure Hardening - access controls, monitoring, administration, service levels, physical security, etc.
Security Policy and Awareness efforts ? Increased control requirements for processes and systems that support High Value Information Assets and greater investments in Awareness activities for staff that make use of High Value Information.
Security Technology Investments can be directed and used more wisely
Focusing or redirecting SIEM, DLP, and other network based security controls to higher value assets and away from lower value.
?? Cost savings and/or Cost Avoidance by redirecting effort and energy away from less valuable information ? yes, this can and does happen. When a company?s leadership has agreed to what information is most valuable to protect, then it much easier to reduce control costs and accept risks associated with lower value information.
?? Vendor Management and 3rd Party Risk Management process improvement and decision making, based upon access to and transfer of high value information.
?? Reduced legal exposure via a documented, defensible, and agreed to prioritization of a company?s most valuate information assets and subsequent decisions in control investments. You are in a much better position or at least have a good ?1st Line of Defense?, if you have engaged a cross-functional group of business stakeholders that have agreed to what is most important and documented their decisions, than if you DON?T have this.? Even if you what you have is not perfect, at least you have demonstrated some initial due diligence?
If you would like some additional perspectives on High Value Information Assets, here is a good article of a security practioner?I work with, Tim Layton,?and what he refers to as Data Classication: Next Level.
I welcome your comments.
Mark Brooks
You can follow me on Twitter at https://twitter.com/#!/wmarkbrooks
You can connect with on LinkedIn at http://www.linkedin.com/in/wmarkbrooks
Two weeks after arriving into JFK on the back of a Boeing 747, the Enterprise has been hoisted from the back of the jet and onto a wheeled transporter. From there, the prototype spacecraft will be taken down the Hudson river on a barge, where it'll end up exhibited on the flight desk of the USS Intrepid (CV-11). The museum will open on July 19th, while the plane that carried it has one more historic flight to carry out -- taking the Endeavour to the California Science Center before both are retired.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_uB4Lw-cUudYt2WiH6Oa6k1DGj28D1MUx0d0IYeA4ABvFDr2fN-aR29Q2Emc6FSDkTP5g0sZa80uWTQpGfXuBh8-xsCCtNJQMdJG7uVnok=s0-d){kind=small}
Public release date: 3-Jul-2012
Share ] 
As a follow on to my blogpost on High Value Data Information Governance, I thought I would share some additional benefits that company's often realize when they have been able to effectively identify and assess risk for their most valuable information.
